View Item 

Show simple item record

Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI
dc.contributor.authorPatel, Richa
dc.contributor.authorAslam, Anum
dc.contributor.authorParikh, Neehar D.
dc.contributor.authorMervak, Benjamin
dc.contributor.authorMubarak, Eman
dc.contributor.authorHiggins, Lily
dc.contributor.authorLala, Kayli
dc.contributor.authorConner, Jack F.
dc.contributor.authorKhaykin, Valerie
dc.contributor.authorBashir, Mustafa
dc.contributor.authorDo, Richard Kinh Gian
dc.contributor.authorBurke, Lauren M. B.
dc.contributor.authorSmith, Elainea N.
dc.contributor.authorKim, Charles Y.
dc.contributor.authorShampain, Kimberly L.
dc.contributor.authorOwen, Dawn
dc.contributor.authorMendiratta-Lala, Mishal
dc.date.accessioned2023-06-01T20:48:35Z
dc.date.available2024-07-01 16:48:31en
dc.date.available2023-06-01T20:48:35Z
dc.date.issued2023-06
dc.identifier.citationPatel, Richa; Aslam, Anum; Parikh, Neehar D.; Mervak, Benjamin; Mubarak, Eman; Higgins, Lily; Lala, Kayli; Conner, Jack F.; Khaykin, Valerie; Bashir, Mustafa; Do, Richard Kinh Gian; Burke, Lauren M. B.; Smith, Elainea N.; Kim, Charles Y.; Shampain, Kimberly L.; Owen, Dawn; Mendiratta-Lala, Mishal (2023). "Updates on LI- RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI." Journal of Magnetic Resonance Imaging 57(6): 1641-1654.
dc.identifier.issn1053-1807
dc.identifier.issn1522-2586
dc.identifier.urihttps://hdl.handle.net/2027.42/176825
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherlocoregional therapy
dc.subject.otherhepatocellular carcinoma
dc.subject.othertreatment response assessment
dc.subject.otherLiver Imaging Data and Reporting System treatment response algorithm
dc.titleUpdates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176825/1/jmri28659_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176825/2/jmri28659.pdf
dc.identifier.doi10.1002/jmri.28659
dc.identifier.sourceJournal of Magnetic Resonance Imaging
dc.identifier.citedreferenceKim DH, Kim B, Choi JI, Oh SN, Rha SE. LI-RADS treatment response versus modified RECIST for diagnosing viable hepatocellular carcinoma after locoregional therapy: A systematic review and meta-analysis of comparative studies. Taehan Yongsang Uihakhoe chi 2022; 83 ( 2 ): 331 - 343.
dc.identifier.citedreferenceMendiratta-Lala M, Gu E, Owen D, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2018; 102 ( 4 ): 1063 - 1069.
dc.identifier.citedreferenceMendiratta-Lala M, Masch W, Owen D, et al. Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY) 2020; 45: 3698 - 3708.
dc.identifier.citedreferenceBrook OR, Thornton E, Mendiratta-Lala M, et al. CT imaging findings after stereotactic radiotherapy for liver tumors. Gastroenterol Res Pract 2015; 2015: 126245.
dc.identifier.citedreferenceRiaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49 ( 4 ): 1185 - 1193.
dc.identifier.citedreferenceMendiratta-Lala M, Aslam A, Maturen KE, et al. LI-RADS treatment response algorithm: Performance and diagnostic accuracy with radiologic-pathologic explant correlation in patients with SBRT-treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2022; 112 ( 3 ): 704 - 714.
dc.identifier.citedreferenceShropshire EL, Chaudhry M, Miller CM, et al. LI-RADS treatment response algorithm: Performance and diagnostic accuracy. Radiology 2019; 292 ( 1 ): 226 - 234.
dc.identifier.citedreferenceSeo N, Kim MS, Park MS, et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with liver imaging reporting and data system version 2017. Eur Radiol 2020; 30 ( 1 ): 261 - 271.
dc.identifier.citedreferenceOrmiston WEL, Yarmohammadi H, Lobaugh S, et al. Post-treatment CT LI-RADS categories: Predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY) 2021; 46 ( 8 ): 3738 - 3747.
dc.identifier.citedreferenceMendiratta-Lala M, Masch W, Shankar PR, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: Long term imaging follow-up. Int J Radiat Oncol Biol Phys 2019; 103 ( 1 ): 169 - 179.
dc.identifier.citedreferenceKim DW, Choi SH, Lee JS, Kim SY, Lee SJ, Byun JH. Interreader reliability of liver imaging reporting and data system treatment response: A systematic review and meta-analysis. Diagnostics (Basel) 2021; 11 ( 2 ): 237.
dc.identifier.citedreferenceAbdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab R. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy. Diagn Interv Imaging 2020; 547 - 553.
dc.identifier.citedreferenceChaudhry M, McGinty KA, Mervak B, et al. The LI-RADS version 2018 mri treatment response algorithm: Evaluation of ablated hepatocellular carcinoma. Radiology 2020; 294 ( 2 ): 320 - 326.
dc.identifier.citedreferenceCools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the liver imaging reporting and data system treatment response criteria after thermal ablation for hepatocellular carcinoma. Liver Transpl 2020; 26 ( 2 ): 203 - 214.
dc.identifier.citedreferenceKim SW, Joo I, Kim HC, et al. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: Diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020; 30 ( 5 ): 2861 - 2870.
dc.identifier.citedreferencePark S, Joo I, Lee DH, et al. Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: Adding ancillary features to MRI compared with enhancement patterns at CT and MRI. Radiology 2020; 83 ( 2 ): 192797.
dc.identifier.citedreferenceKim TH, Woo S, Joo I, et al. LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: A systematic review and meta-analysis using individual patient data. Abdom Radiol (NY) 2021; 46 ( 8 ): 3717 - 3728.
dc.identifier.citedreferenceGupta P, Bansal A, Das GC, et al. Diagnostic accuracy of liver imaging reporting and data system locoregional treatment response criteria: A systematic review and meta-analysis. Eur Radiol 2021; 31 ( 10 ): 7725 - 7733.
dc.identifier.citedreferenceNathani P, Gopal P, Rich N, et al. Hepatocellular carcinoma tumour volume doubling time: A systematic review and meta-analysis. Gut 2021; 70 ( 2 ): 401 - 407.
dc.identifier.citedreferenceBartnik K, Podgórska J, Rosiak G, Korzeniowski K, Rowiński O. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization. Abdom Radiol (NY) 2022; 47 ( 1 ): 115 - 122.
dc.identifier.citedreferenceKierans AS, Najjar M, Dutruel SP, et al. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization. Clin Imaging 2021; 80: 117 - 122.
dc.identifier.citedreferenceHuh YJ, Kim DH, Kim B, Choi JI, Rha SE. Per-feature accuracy of liver imaging reporting and data system locoregional treatment response algorithm: A systematic review and meta-analysis. Cancers (Basel) 2021; 13 ( 17 ): 4432.
dc.identifier.citedreferenceSalem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY Study. Hepatology 2021; 74 ( 5 ): 2342 - 2352.
dc.identifier.citedreferenceMathew AS, Atenafu EG, Owen D, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020; 134: 41 - 51.
dc.identifier.citedreferenceMastrocostas K, Fischer S, Munoz-Schuffenegger P, et al. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdom Radiol (NY) 2021; 46 ( 4 ): 1572 - 1585.
dc.identifier.citedreferenceSchaub SK, Hartvigson PE, Lock MI, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 2018; 17: 1533033818790217.
dc.identifier.citedreferenceReig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76 ( 3 ): 681 - 693.
dc.identifier.citedreferenceJiao Y, Cao F, Liu H. Radiation-induced cell death and its mechanisms. Health Phys 2022; 123 ( 5 ): 376 - 386.
dc.identifier.citedreferenceKeppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007; 188 ( 3 ): 768 - 775.
dc.identifier.citedreferenceKing MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: Inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol 2020; 133: 109351.
dc.identifier.citedreferenceVietti Violi N, Gnerre J, Law A, et al. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: Correlation with histopathology. Eur Radiol 2022; 32 ( 9 ): 6493 - 6503.
dc.identifier.citedreferenceCerny M, Chernyak V, Olivié D, et al. LI-RADS version 2018 ancillary features at MRI. Radiographics 2018; 38 ( 7 ): 1973 - 2001.
dc.identifier.citedreferenceKim YY, Kim MJ, Yoon JK, Shin J, Roh YH. Incorporation of ancillary MRI features into the LI-RADS treatment response algorithm: Impact on diagnostic performance after locoregional treatment of hepatocellular carcinoma. AJR Am J Roentgenol 2022; 218 ( 3 ): 484 - 493.
dc.identifier.citedreferenceYu JS, Kim JH, Chung JJ, Kim KW. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 2009; 30 ( 1 ): 153 - 160.
dc.identifier.citedreferencePark S, Joo I, Lee DH, et al. Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: Adding ancillary features to MRI compared with enhancement patterns at CT and MRI. Radiology 2020; 296 ( 3 ): 554 - 561.
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 ( 6 ): 394 - 424.
dc.identifier.citedreferenceHeimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 ( 1 ): 358 - 380.
dc.identifier.citedreferenceAllard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 2015; 63 ( 1 ): 83 - 92.
dc.identifier.citedreferenceBelghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford) 2005; 7 ( 1 ): 42 - 49.
dc.identifier.citedreferenceVoizard N, Cerny M, Assad A, et al. Assessment of hepatocellular carcinoma treatment response with LI-RADS: A pictorial review. Insights Imaging 2019; 10 ( 1 ): 121.
dc.identifier.citedreferenceThe LI-RADS v2018 Manual. 2018; Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/LI-RADS-2018-Manual-5Dec18.pdf?la=en.
dc.identifier.citedreferenceAmerican College of Radiology. Liver Imaging Reporting and Data System Version 2018 Manual. 2018.
dc.identifier.citedreferenceElhalawani H, Lin TA, Volpe S, et al. Machine learning applications in head and neck radiation oncology: Lessons from open-source radiomics challenges. Front Oncol 2018; 8: 294.
dc.identifier.citedreferenceSia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: A primer. Front Cell Dev Biol 2020; 8: 41.
dc.identifier.citedreferenceGolden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2: 88.
dc.identifier.citedreferenceAslam A, Do RKG, Kambadakone A, et al. Hepatocellular carcinoma liver imaging reporting and data systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12 ( 10 ): 738 - 753.
dc.identifier.citedreferenceGuan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004; 10 ( 24 ): 3543 - 3548.
dc.identifier.citedreferenceTian G, Yang S, Yuan J, et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: Systematic review and network meta-analysis. BMJ Open 2018; 8 ( 10 ): e021269.
dc.identifier.citedreferenceKloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 ( 3 ): 532 - 540.
dc.identifier.citedreferenceDioguardi Burgio M, Sartoris R, Libotean C, et al. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging 2019; 19 ( 1 ): 75.
dc.identifier.citedreferenceKim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35 ( 11 ): 1343 - 1350.
dc.identifier.citedreferenceLetzen BS, Malpani R, Miszczuk M, et al. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clin Imaging 2021; 78: 194 - 200.
dc.identifier.citedreferenceMiszczuk MA, Chapiro J, Geschwind JH, et al. Lipiodol as an imaging biomarker of tumor response after conventional transarterial chemoembolization: Prospective clinical validation in patients with primary and secondary liver cancer. Transl Oncol 2020; 13 ( 3 ): 100742.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jmri28659_am.pdf
Size:
34.60MB
Format:
PDF
View/Open
Name:
jmri28659.pdf
Size:
1.531MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.